Harrow (NASDAQ:HROW - Get Free Report) is anticipated to post its Q1 2025 quarterly earnings results before the market opens on Monday, May 12th. Analysts expect Harrow to post earnings of $0.02 per share and revenue of $57.00 million for the quarter.
Harrow (NASDAQ:HROW - Get Free Report) last released its quarterly earnings results on Thursday, March 27th. The company reported $0.25 earnings per share for the quarter, topping analysts' consensus estimates of $0.11 by $0.14. The company had revenue of $66.83 million during the quarter, compared to analysts' expectations of $66.01 million. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. On average, analysts expect Harrow to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Harrow Stock Up 3.3 %
HROW opened at $25.83 on Monday. The business's fifty day simple moving average is $25.08 and its 200 day simple moving average is $33.62. Harrow has a 52 week low of $10.08 and a 52 week high of $59.23. The firm has a market cap of $947.57 million, a P/E ratio of -27.48 and a beta of 0.41. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently commented on HROW shares. HC Wainwright reiterated a "buy" rating and set a $57.00 price target on shares of Harrow in a report on Monday, March 31st. B. Riley lowered their target price on shares of Harrow from $69.00 to $65.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st.
Read Our Latest Research Report on Harrow
Harrow Company Profile
(
Get Free Report)
Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Harrow, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harrow wasn't on the list.
While Harrow currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.